Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GALLANT: A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab as Second/Third Line Therapy for Advanced Sarcoma

NCT04535713 is registered in ClinicalTrials.gov with Sarcoma Oncology Research Center, LLC as lead sponsor.

NCT NCT04535713
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04535713 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GALLANT: A Phase 2 Study Using Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab as Second/Third Line Therapy for Advanced Sarcoma
Lead sponsor
Sarcoma Oncology Research Center, LLC
Phase
Phase 2
Overall status
Unknown status
Start date
September 30, 2020
Completion date
December 31, 2025
Enrollment
260 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sarcoma